# A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer

> **NCT04975061** · — · UNKNOWN · sponsor: **Shanghai YingLi Pharmaceutical Co. Ltd.** · enrollment: 58 (estimated)

## Conditions studied

- Effectiveness，Safety，Thymic Cancer

## Interventions

- **DRUG:** YY-20394

## Key facts

- **NCT ID:** NCT04975061
- **Lead sponsor:** Shanghai YingLi Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-30
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04975061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04975061, "A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04975061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*